Education
About Us
Working with TipRanks
Follow Us
Bio-Gene Technology Ltd. (AU:BGT)
ASX:BGT
BGT Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.02
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.06
Previous CloseN/A
Volume38.03K
Average Volume (3M)988.87K
Market Cap
AU$10.68M
Enterprise ValueAU$9.90M
Total Cash (Recent Filing)AU$1.08M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta-0.71
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding305,061,100
10 Day Avg. Volume246,330
30 Day Avg. Volume988,871
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)2.08
Price to Sales (P/S)0.00
P/FCF Ratio-1.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Minimal DebtA near-zero debt profile materially reduces refinancing and interest-rate risk, giving the company structural financial flexibility. Over a 2–6 month horizon this lowers bankruptcy risk and improves the ability to raise equity or partner for development without immediate solvency pressure.
Improved Free Cash Flow Trend (2025 Vs 2024)A year-over-year improvement in free cash flow, even from a negative base, suggests nascent operational stabilization or better cash discipline. This durable trend can reduce future funding needs and supports longer-term planning, making the business slightly less reliant on immediate external financing.
Losses Not Accelerating MateriallyStable (non-accelerating) losses imply management may be containing costs and avoiding sharp deterioration. Over months this steadiness aids forecasting, preserves optionality for strategic partnerships or milestone-based financing, and reduces the risk of sudden balance-sheet shocks.
Bears Say
Revenue Collapsed To Effectively ZeroNear-zero revenue is a structural red flag for commercial viability: it implies the company lacks scalable product sales and remains development-stage. Over a multi-month horizon this forces reliance on external capital, increases dilution risk, and weakens long-term self-sustaining growth prospects.
Persistent Operating Cash BurnConsistent negative operating and free cash flows mean the business consumes cash to operate. This enduring cash burn necessitates repeated financing or partnerships, constraining strategic options, pressuring margins, and raising funding risk over the next several months if capital markets tighten.
Material Erosion Of EquityA shrinking equity base from sustained losses reduces the firm's net worth and its ability to absorb setbacks. Over a 2–6 month horizon this weakens creditworthiness and shareholder cushion, increasing vulnerability to adverse events and limiting capacity for organic investment without dilution.
Bio-Gene Technology Ltd. News
BGT FAQ
What was Bio-Gene Technology Ltd.’s price range in the past 12 months?
Bio-Gene Technology Ltd. lowest share price was AU$0.02 and its highest was AU$0.06 in the past 12 months.
What is Bio-Gene Technology Ltd.’s market cap?
Bio-Gene Technology Ltd.’s market cap is AU$10.68M.
When is Bio-Gene Technology Ltd.’s upcoming earnings report date?
Bio-Gene Technology Ltd.’s upcoming earnings report date is Aug 20, 2026 which is in 158 days.
How were Bio-Gene Technology Ltd.’s earnings last quarter?
Bio-Gene Technology Ltd. released its earnings results on Mar 04, 2026. The company reported -AU$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.005.
Is Bio-Gene Technology Ltd. overvalued?
According to Wall Street analysts Bio-Gene Technology Ltd.’s price is currently Overvalued.
Does Bio-Gene Technology Ltd. pay dividends?
Bio-Gene Technology Ltd. does not currently pay dividends.
What is Bio-Gene Technology Ltd.’s EPS estimate?
Bio-Gene Technology Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bio-Gene Technology Ltd. have?
Bio-Gene Technology Ltd. has 305,061,100 shares outstanding.
What happened to Bio-Gene Technology Ltd.’s price movement after its last earnings report?
Bio-Gene Technology Ltd. reported an EPS of -AU$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.714%.
Which hedge fund is a major shareholder of Bio-Gene Technology Ltd.?
Currently, no hedge funds are holding shares in AU:BGT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bio-Gene Technology Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:BGT Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-52.63%
12-Months-Change
Fundamentals
Return on Equity
-140.35%
Trailing 12-Months
Asset Growth
-21.07%
Trailing 12-Months
Company Description
Bio-Gene Technology Ltd.
Bio-Gene Technology Limited, an agtech development company, engages in developing and commercializing insecticides/pesticides for animal health, crop protection, public health, and consumer applications in Australia. Its lead products include Flavocide, a beta-triketone insecticide product; and Qcide, a natural oil extracted from a cultivar of eucalyptus cloeziana. The company has a research collaboration agreement with James Cook University for the development of a tissue culture system to support the expansion of tree plantations and scale-up of future Qcide oil production. It also has research collaborations with BASF, Grains Research and Development Corporation, and Queensland Department of Agriculture and Fisheries for assessing activity against grain storage pests. Bio-Gene Technology Limited was incorporated in 1995 and is based in Melbourne, Australia.
Technical Analysis
Zelira Therapeutics
―
Invex Therapeutics Ltd.
―
Regeneus Ltd.
―
AdAlta Ltd.
―
Hexima Ltd
―
Options Prices
Currently, No data available
---